Neurogene Inc. announced positive interim clinical data from its Phase 1/2 open-label trial of NGN-401 gene therapy for Rett syndrome in female pediatric patients. The low-dose cohort demonstrated a favorable safety profile and meaningful skills and developmental milestones improvements. These improvements were consistent across multiple assessment scales and exceeded expectations based on the natural progression of Rett syndrome.